Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 308
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03406507 | A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria | ||
| NCT04248465 | An Efficacy and Safety Study of Ravulizumab in ALS Participants | ||
| NCT05319899 | A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults | ||
| NCT00984113 | Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment | ||
| NCT02145182 | Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study) | ||
| NCT04940559 | Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants | ||
| NCT05751642 | Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants | ||
| NCT02345421 | A Study to Identify and Characterize LAL-D Patients in High-risk Populations | ||
| NCT07218887 | ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy | ||
| NCT04935294 | Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction | ||
| NCT03748823 | Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab | ||
| NCT05288660 | A Study of a Single Dose of ALXN1210 in Healthy Participants | ||
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | ||
| NCT01919346 | Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation | ||
| NCT03468140 | Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation | ||
| NCT05708573 | Potential Drug Interaction Between ALXN2040 and Rosuvastatin | ||
| NCT05239221 | AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism | ||
| NCT03310021 | A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects | ||
| NCT05303324 | Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults | ||
| NCT05746559 | ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE | ||
| NCT04709081 | A Drug Interaction Study of ACH-0145228 | ||
| NCT01221181 | Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy | ||
| NCT04660890 | A Study of the Cardiac Effects of ALXN2050 in Healthy Adults | ||
| NCT07306949 | Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers | ||
| NCT04189315 | Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease | ||
| NCT03329365 | Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS | ||
| NCT01275287 | Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab | ||
| NCT03384186 | A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants | ||
| NCT03218241 | Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote | ||
| NCT05288816 | A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants | ||
| NCT05314231 | Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria | ||
| NCT00894075 | Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) | ||
| NCT07337395 | Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab | ||
| NCT02245867 | Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | ||
| NCT00935883 | Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) | ||
| NCT02987504 | Study of Samalizumab in Patients With Advanced Cancer | ||
| NCT04573309 | Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 | ||
| NCT01895127 | Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation | ||
| NCT04631562 | Study of ALXN1820 in Healthy Adult Participants | ||
| NCT00742859 | Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin | ||
| NCT06607627 | PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | ||
| NCT02090179 | Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging | ||
| NCT00838513 | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT00844428 | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS | ||
| NCT06015750 | Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia | ||
| NCT06830798 | Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation | ||
| NCT05578846 | Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics | ||
| NCT01671956 | Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis | ||
| NCT06079281 | Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa | ||
| NCT02605993 | Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) |
